B
ecause atrial fibrillation (AF) may be paroxysmal and asymptomatic, stroke can be the first clinically recognized manifestation of AF. Recently, large-scale screening efforts for AF have been designed with the goal of preventing strokes through the early identification of AF. [1] [2] [3] Opportunistic screening for AF in patients aged ≥65 has been endorsed. 4 The cost effectiveness of such efforts may be significantly influenced by the frequency with which individuals with AF initially present with a stroke. Yet, to date, cost-effectiveness data 2, 3, 5, 6 have generally relied on assumptions of stroke rates observed in patients with established AF, whereas incidence rates of undiagnosed AF presenting as a stroke remain unclear. To characterize strokes occurring as the initial manifestation of AF, we assessed incident strokes that occurred ≤1 year before AF detection in the community-based FHS (Framingham Heart Study).
Methods
Participants from the FHS original and offspring cohorts were eligible for this study. 7, 8 Of 2032 individuals with AF, we excluded those who did not attend a study examination within 10 years before firstdetected AF (n=223). We included 1809 individuals with incident AF between 1951 and 2013. The Boston University Medical Center Institutional Review Board approved study protocols, and participants provided consent at each cycle.
Participants were classified as having AF if AF or atrial flutter was present on an ECG obtained at an FHS clinic visit (about every 2 years for original cohort and every 4-8 years for offspring cohort) or was identified in an encounter with external clinicians by ambulatory cardiac monitoring, or documented in hospital records, as previously described. 9 Strokes were defined as acute-onset neurological deficits of presumed or definite vascular pathogenesis persisting for at least 24 hours, whereas transient ischemic attacks were defined as those lasting <24 hours. Imaging studies, noninvasive vascular studies, cardiac evaluations, and information from autopsies were used to ascertain stroke status. Two cardiologists adjudicated first-detected Background and Purpose-To prevent strokes that may occur as the first manifestation of atrial fibrillation (AF), screening programs have been proposed to identify patients with undiagnosed AF who may be eligible for treatment with anticoagulation. However, the frequency with which patients with AF present with stroke as the initial manifestation of the arrhythmia is unknown. Methods-We estimated the frequency with which AF may present as a stroke in 1809 community-based Framingham Heart
Study participants with first-detected AF and without previous strokes, by tabulating the frequencies of strokes occurring on the same day, within 30 days before, 90 days before, and 365 days before first-detected AF. Using previously reported AF incidence rates, we estimated the incidence of strokes that may represent the initial manifestation of AF. Results-We observed 87 strokes that occurred ≤1 year before AF detection, corresponding to 1.7% on the same day, 3.4% within 30 days before, 3.7% within 90 days before, and 4.8% ≤1 year before AF detection. We estimated that strokes may present as the initial manifestation of AF at a rate of 2 to 5 per 10 000 person-years, in both men and women. Conclusions-We observed that stroke is an uncommon but measureable presenting feature of AF. Our data imply that emphasizing cost-effectiveness of population-wide AF-screening efforts will be important given the relative infrequency with which stroke represents the initial manifestation of AF. To determine the proportion of individuals with AF who presented with stroke before AF detection, we tabulated the number of individuals with strokes occurring at or before AF in several temporal windows (ie, same day, within 30 days before, within 90 days before, and within 365 days before). We selected 365 days a priori under the assumption that strokes were less likely to be related to AF the longer the window between stroke and first detected AF. We stratified stroke events by sex and age of first-detected AF (<65, 65-74, and ≥75 years). To estimate the incidence of stroke occurring as the initial manifestation of AF, we multiplied the proportion of individuals with first-detected AF with a stroke by previously published FHS AF incidence rates. 10 Analyses were conducted using SAS version 9.3 for Windows (SAS Institute, Cary, NC).
Results
Of the 1809 individuals with incident AF, the mean age at firstdetected AF was 74.6±11.2 years, and 857 individuals (47%) were women. Eighty-seven strokes occurred ≤1 year before AF detection, of which 82 strokes (94%) were ischemic. Thirty individuals (1.7%) had strokes that occurred on the same day as the first-detected AF event, 61 (3.4%) occurred within 30 days before AF detection, 67 (3.7%) within 90 days, and 87 (4.8%) ≤1 year before AF detection (Figure) . As expected, the proportion of individuals with stroke was generally greater among women than men and was greater with older age. The results did not differ substantively if the data were restricted to ischemic strokes.
By extrapolating these observations ( Table) , we estimate that for both men and women, ≈2 to 5 individuals per 10 000 person-years may present with stroke as the initial manifestation of AF (based on an AF incidence rate of 134 cases per 10 000 person-years in men and 86 cases per 10 000 personyears in women).
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Discussion
In our community-based sample of 1809 individuals with AF detected during a 60-year period, we observed that between 2% and 5% presented with a stroke or transient ischemic attack at or in near proximity before the AF diagnosis. Our data extend previous knowledge by suggesting that stroke is an uncommon but measurable presenting feature of AF.
Assuming that strokes occurring in close proximity to an AF diagnosis are attributable to AF and are preventable with anticoagulation, our observations imply that population-wide AF-screening efforts with pulse checks, mobile technology, or other modalities 11 may be effective for reducing the incidence of stroke. However, cost-effective screening efforts are paramount, given the relative infrequency with which strokes present as the first manifestation of AF. Cost-effectiveness analyses will be informed by future data addressing the prevalence of undiagnosed AF in different stroke risk strata; prevalence of paroxysmal versus persistent AF (the latter of which may be easier to identify with AF screening interventions); and the accuracy, modality, patient adherence, and costs associated with different screening efforts. Such efforts are likely to be of greatest value among individuals with the highest stroke risks, who are eligible for anticoagulation if AF is identified through screening.
We acknowledge that we may have underestimated the frequency of AF-associated stroke, particularly if such strokes were severely disabling or fatal, if AF was unrecognized, or if 
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AF occurred only as an isolated episode. Moreover, although we examined time windows ≤365 days preceding an AF event, we acknowledge that strokes occurring >365 days before an AF event may be related to undetected arrhythmia. Our sample was predominantly of European ancestry, and therefore, our findings may not be generalizable to other racial or ethnic groups. Our analysis spanned multiple decades, and era-specific factors may have influenced the probability of AF and stroke detection. Data from the Framingham Heart Study indicate that recently observed growth in AF incidence was partially attributable to increases in cardiac rhythm surveillance over time. 10 Not all strokes may have been of cardioembolic origin from AF. Some of the AF events may have occurred as a consequence of stroke, 12 rather than being causally related to the stroke. However, most AF observed at the time of an acute stroke has been reported to coexist long term. 13 
Conclusions
In conclusion, we observed that strokes are uncommon but may represent the first presentation of AF. The utility and cost effectiveness of efforts to reduce stroke by identifying individuals with undiagnosed AF require prospective evaluation. 
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